Antiglaucoma EP2 Agonists: A Long Road That Led Somewhere.
J Ocul Pharmacol Ther
; 35(9): 469-474, 2019 Nov.
Article
em En
| MEDLINE
| ID: mdl-31329508
ABSTRACT
For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP2 agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Glaucoma
/
Receptores de Prostaglandina E Subtipo EP2
/
Anti-Hipertensivos
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article